MoonLake Immunotherapeutics (MLTX) Stock Analysis

What MoonLake Immunotherapeutics does

MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.

Key metrics

ETFs linked to MLTX

Broad-market and Healthcare sector ETFs an investor holding MoonLake Immunotherapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how MLTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics trades under the ticker MLTX on NASDAQ.

Which exchange is MLTX listed on?

MLTX is listed on NASDAQ.

What sector does MoonLake Immunotherapeutics operate in?

MoonLake Immunotherapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze MLTX in a portfolio?

PortView shows MLTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.